SAN

88.8

-1.15%↓

SHL.DE

48.14

-1.61%↓

ARGX

477.1

-2.55%↓

FRE

41.77

-1.28%↓

ONC.US

219.73

-1.77%↓

SAN

88.8

-1.15%↓

SHL.DE

48.14

-1.61%↓

ARGX

477.1

-2.55%↓

FRE

41.77

-1.28%↓

ONC.US

219.73

-1.77%↓

SAN

88.8

-1.15%↓

SHL.DE

48.14

-1.61%↓

ARGX

477.1

-2.55%↓

FRE

41.77

-1.28%↓

ONC.US

219.73

-1.77%↓

SAN

88.8

-1.15%↓

SHL.DE

48.14

-1.61%↓

ARGX

477.1

-2.55%↓

FRE

41.77

-1.28%↓

ONC.US

219.73

-1.77%↓

SAN

88.8

-1.15%↓

SHL.DE

48.14

-1.61%↓

ARGX

477.1

-2.55%↓

FRE

41.77

-1.28%↓

ONC.US

219.73

-1.77%↓

Search

Laboratorios Farmaceuticos Rovi SA

Suletud

SektorTervishoid

52.6 -1.59

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

52.55

Max

53.75

Põhinäitajad

By Trading Economics

Sissetulek

-57M

32M

Müük

199M

434M

P/E

Sektori keskmine

20.225

56.602

Aktsiakasum

0.457

Dividenditootlus

2.15

Kasumimarginaal

7.411

Töötajad

2,197

EBITDA

40M

138M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+45.46% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

2.15%

2.45%

Järgmine tulemuste avaldamine

30. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

-643M

2.8B

Eelmine avamishind

54.19

Eelmine sulgemishind

52.6

Uudiste sentiment

By Acuity

50%

50%

187 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. mai 2025, 23:40 UTC

Kuumad aktsiad

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14. mai 2025, 23:33 UTC

Suurimad hinnamuutused turgudel

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14. mai 2025, 23:25 UTC

Suurimad hinnamuutused turgudel

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14. mai 2025, 23:25 UTC

Tulu

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14. mai 2025, 22:58 UTC

Tulu

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14. mai 2025, 21:35 UTC

Tulu

Cisco Systems Names Patterson as CFO, Patel as President

14. mai 2025, 23:59 UTC

Market Talk

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14. mai 2025, 23:49 UTC

Market Talk

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14. mai 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

14. mai 2025, 23:48 UTC

Market Talk

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14. mai 2025, 23:47 UTC

Market Talk

Gold Gains on Possible Technical Recovery -- Market Talk

14. mai 2025, 23:34 UTC

Omandamised, ülevõtmised, äriostud

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14. mai 2025, 23:10 UTC

Tulu

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14. mai 2025, 23:07 UTC

Tulu

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14. mai 2025, 23:00 UTC

Peamised uudised

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14. mai 2025, 22:43 UTC

Tulu

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14. mai 2025, 22:34 UTC

Tulu

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14. mai 2025, 22:33 UTC

Tulu

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14. mai 2025, 22:30 UTC

Tulu

Xero Did Not Declare a Dividend>XRO.AU

14. mai 2025, 22:30 UTC

Tulu

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14. mai 2025, 22:30 UTC

Tulu

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14. mai 2025, 22:30 UTC

Tulu

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14. mai 2025, 22:28 UTC

Tulu

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14. mai 2025, 22:28 UTC

Tulu

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14. mai 2025, 22:27 UTC

Tulu

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14. mai 2025, 22:27 UTC

Tulu

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14. mai 2025, 22:23 UTC

Peamised uudised

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14. mai 2025, 22:15 UTC

Tulu

Correction to Cisco Earnings Article -- WSJ

14. mai 2025, 21:48 UTC

Tulu

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14. mai 2025, 21:37 UTC

Tulu

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Laboratorios Farmaceuticos Rovi SA Prognoos

Hinnasiht

By TipRanks

45.46% tõus

12 kuu keskmine prognoos

Keskmine 77.75 EUR  45.46%

Kõrge 90 EUR

Madal 65.5 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

51.1 / N/AToetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

187 / 382 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.